Moderna Inc (Moderna) is a biotechnology company that develops therapeutics and vaccines based on messenger RNA (mRNA) for the treatment of infectious diseases, rare diseases, immuno-oncology, cardiovascular diseases, and auto-immune diseases. It is pioneering a new class of medicines made of mRNA with significant potential to improve the lives of patients. The implications of using mRNA as a drug help to improve how medicines are discovered, developed, manufactured and administered.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on developing technologies that enable the development of mRNA medicines for diverse applications. The company has 48 development programs, which include 38 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, localized regenerative therapeutics, systemic intracellular therapeutics, intratumoral immuno-oncology, and inhaled pulmonary therapeutics. In FY2022, the company spent US$3,295 million on its R&D activities, which as a percentage of revenue stood at 17.1%, and grew 65.5% YoY.